2. Signaling Pathways
  3. Immunology/Inflammation
  4. PSMA

PSMA

Prostate-specific membrane antigen

 

PSMA Related Products (20):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125399
    PSMA-11
    		99.74%
    PSMA-11 is a positron emission tomography (PET) tracer. PSMA-11 detects prostate cancer relapses and metastases by binding to the extracellular domain of prostate-specific membrane antigen (PSMA).
    PSMA-11
  • HY-P99239
    Rosopatamab
    		99.50%
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency.
    Rosopatamab
  • HY-148152A
    PSMA I&S TFA
    		98.15%
    PSMA I&S (TFA) is a precursor of the 99mTc-labeled PSMA-targeting ligand.
    PSMA I&S TFA
  • HY-103591
    DUPA(OtBu)-OH
    		≥98.0%
    DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
    DUPA(OtBu)-OH
  • HY-P10055A
    PSMA targeting peptide TFA
    		99.09%
    PSMA targeting peptide TFA (PSMA-1 TFA) is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells.
    PSMA targeting peptide TFA
  • HY-158123
    PSMA binder-1
    PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or it can be labeled with 225Ac (to obtain Actinium-225-PSMA-Trillium (BAY 3563254)), which has a radioactive killing effect; it can be used as a Macropa chelator for targeted radionuclide therapy (TRT) , has a strong inhibitory effect on metastatic castration-resistant prostate cancer (mCRPC).
    PSMA binder-1
  • HY-163196
    PSMA-IN-4
    		Inhibitor
    PSMA-IN-4 (compound 9) is a potent inhibitor of PSMA, with the IC50 value of 1.2 μM.
    PSMA-IN-4
  • HY-147287
    Glu-urea-Glu-NHS ester
    Glu-urea-Glu-NHS ester (compound 21) is an activated N-hydroxysuccinamide (NHS) ester of Glu-urea-Glu which can be used as a pharmacophore for linking with prostate specific membrane antigen (PSMA) inhibitors.
    Glu-urea-Glu-NHS ester
  • HY-P5290
    HYNIC-PSMA
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research.
    HYNIC-PSMA
  • HY-153550
    PSMA-1007
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging.
    PSMA-1007
  • HY-158125
    PSMA binder-2
    PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC).
    PSMA binder-2
  • HY-P5990
    Prostate Specific Antigen Substrate
    Prostate Specific Antigen Substrate is a prostate specific antigen (PSA) fluorescent substrate. Prostate Specific Antigen Substrate can be used for detect enzymatic activity of PSA.
    Prostate Specific Antigen Substrate
  • HY-158119
    Ac-PSMA-trillium
    Ac-PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). Ac-PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope 225Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC).
    Ac-PSMA-trillium
  • HY-149297
    PSMA-IN-1
    		Inhibitor
    PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a Ki value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λEX: 620 nm; λEM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer.
    PSMA-IN-1
  • HY-117756
    Piflufolastat
    Piflufolastat (DCFPYL) can be used to the preparation of piflufolastat F 18 (DCFPyL F-18). piflufolastat F 18. Piflufolastat F-18 is an 18F-labelled diagnostic imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA).
    Piflufolastat
  • HY-148152
    PSMA I&S
    PSMA I&S is a precursor of the 99mTc-labeled PSMA-targeting ligand.
    PSMA I&S
  • HY-139670
    PSMA–DA1
    PSMA–DA1 may be a useful PSMA-targeting radiotheranostic agent.
    PSMA–DA1
  • HY-P5292
    HYNIC-iPSMA
    HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity.
    HYNIC-iPSMA
  • HY-149298
    PSMA-IN-2
    		Inhibitor
    PSMA-IN-2 is an inhibitor of PSMA with a Ki value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λEM = 1088 nm, λex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice.
    PSMA-IN-2
  • HY-149869
    PSMA-IN-3
    		Inhibitor
    PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer.
    PSMA-IN-3